Cargando…
The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome
Myelodysplastic syndrome (MDS) is a common hematological malignant disease, characterized by malignant hematopoietic stem cell proliferation in the bone marrow (BM); clinically, it mainly manifests clinically mainly by as pathological hematopoiesis, hemocytopenia, and high-risk transformation to acu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767949/ https://www.ncbi.nlm.nih.gov/pubmed/36569863 http://dx.doi.org/10.3389/fimmu.2022.1078421 |
_version_ | 1784854066311987200 |
---|---|
author | Zheng, Likun Zhang, Lei Guo, Yixuan Xu, Xintong Liu, Zhaoyun Yan, Zhenyu Fu, Rong |
author_facet | Zheng, Likun Zhang, Lei Guo, Yixuan Xu, Xintong Liu, Zhaoyun Yan, Zhenyu Fu, Rong |
author_sort | Zheng, Likun |
collection | PubMed |
description | Myelodysplastic syndrome (MDS) is a common hematological malignant disease, characterized by malignant hematopoietic stem cell proliferation in the bone marrow (BM); clinically, it mainly manifests clinically mainly by as pathological hematopoiesis, hemocytopenia, and high-risk transformation to acute leukemia. Several studies have shown that the BM microenvironment plays a critical role in the progression of MDS. In this study, we specifically evaluated mesenchymal stromal cells (MSCs) that exert immunomodulatory effects in the BM microenvironment. This immunomodulatory effect occurs through direct cell-cell contact and the secretion of soluble cytokines or micro vesicles. Several researchers have compared MSCs derived from healthy donors to low-risk MDS-associated bone mesenchymal stem cells (BM-MSCs) and have found no significant abnormalities in the MDS-MSC phenotype; however, these cells have been observed to exhibit altered function, including a decline in osteoblastic function. This altered function may promote MDS progression. In patients with MDS, especially high-risk patients, MSCs in the BM microenvironment regulate immune cell function, such as that of T cells, B cells, natural killer cells, dendritic cells, neutrophils, myeloid-derived suppressor cells (MDSCs), macrophages, and Treg cells, thereby enabling MDS-associated malignant cells to evade immune cell surveillance. Alterations in MDS-MSC function include genomic instability, microRNA production, histone modification, DNA methylation, and abnormal signal transduction and cytokine secretion. |
format | Online Article Text |
id | pubmed-9767949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97679492022-12-22 The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome Zheng, Likun Zhang, Lei Guo, Yixuan Xu, Xintong Liu, Zhaoyun Yan, Zhenyu Fu, Rong Front Immunol Immunology Myelodysplastic syndrome (MDS) is a common hematological malignant disease, characterized by malignant hematopoietic stem cell proliferation in the bone marrow (BM); clinically, it mainly manifests clinically mainly by as pathological hematopoiesis, hemocytopenia, and high-risk transformation to acute leukemia. Several studies have shown that the BM microenvironment plays a critical role in the progression of MDS. In this study, we specifically evaluated mesenchymal stromal cells (MSCs) that exert immunomodulatory effects in the BM microenvironment. This immunomodulatory effect occurs through direct cell-cell contact and the secretion of soluble cytokines or micro vesicles. Several researchers have compared MSCs derived from healthy donors to low-risk MDS-associated bone mesenchymal stem cells (BM-MSCs) and have found no significant abnormalities in the MDS-MSC phenotype; however, these cells have been observed to exhibit altered function, including a decline in osteoblastic function. This altered function may promote MDS progression. In patients with MDS, especially high-risk patients, MSCs in the BM microenvironment regulate immune cell function, such as that of T cells, B cells, natural killer cells, dendritic cells, neutrophils, myeloid-derived suppressor cells (MDSCs), macrophages, and Treg cells, thereby enabling MDS-associated malignant cells to evade immune cell surveillance. Alterations in MDS-MSC function include genomic instability, microRNA production, histone modification, DNA methylation, and abnormal signal transduction and cytokine secretion. Frontiers Media S.A. 2022-12-07 /pmc/articles/PMC9767949/ /pubmed/36569863 http://dx.doi.org/10.3389/fimmu.2022.1078421 Text en Copyright © 2022 Zheng, Zhang, Guo, Xu, Liu, Yan and Fu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zheng, Likun Zhang, Lei Guo, Yixuan Xu, Xintong Liu, Zhaoyun Yan, Zhenyu Fu, Rong The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome |
title | The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome |
title_full | The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome |
title_fullStr | The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome |
title_full_unstemmed | The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome |
title_short | The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome |
title_sort | immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767949/ https://www.ncbi.nlm.nih.gov/pubmed/36569863 http://dx.doi.org/10.3389/fimmu.2022.1078421 |
work_keys_str_mv | AT zhenglikun theimmunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome AT zhanglei theimmunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome AT guoyixuan theimmunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome AT xuxintong theimmunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome AT liuzhaoyun theimmunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome AT yanzhenyu theimmunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome AT furong theimmunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome AT zhenglikun immunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome AT zhanglei immunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome AT guoyixuan immunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome AT xuxintong immunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome AT liuzhaoyun immunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome AT yanzhenyu immunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome AT furong immunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome |